Supplementary material The Supplementary Material for this article can be found online at: Footnotes 1.^Westmetall (2024)
Ken Fujioka, Clinical Professor of Medicine and Director of the Nutrition and Metabolic Research Center at Scripps Clinic, about the clinical evolution of GLP-1-based therapies
Viral Infections and Incretin Pathways: What the Literature Hints Though limited, some evidence supports this hypothesis: A 2018 study in Cell Reports found that microbial and viral byproducts can stimulate GLP-1 secretion via Toll-like receptor (TLR) activation on L-cells
Prior GLP-1-based medication use The majority of patients (94.2%) had an encounter within the prior year and were therefore included in the switching pattern analysis
Insurers may also calculate that the long-term health care cost savings due to a decline in obesity and related health issues is an attractive reason to pay for the treatments
Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies